CN101384532A - Process for preparing optically active alcohols - Google Patents
Process for preparing optically active alcohols Download PDFInfo
- Publication number
- CN101384532A CN101384532A CNA2007800054584A CN200780005458A CN101384532A CN 101384532 A CN101384532 A CN 101384532A CN A2007800054584 A CNA2007800054584 A CN A2007800054584A CN 200780005458 A CN200780005458 A CN 200780005458A CN 101384532 A CN101384532 A CN 101384532A
- Authority
- CN
- China
- Prior art keywords
- carbonatoms
- phenyl
- fluorophenyl
- substituent
- following formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000004519 manufacturing process Methods 0.000 title claims description 18
- 150000001298 alcohols Chemical class 0.000 title description 2
- 238000000034 method Methods 0.000 claims abstract description 37
- 229910000033 sodium borohydride Inorganic materials 0.000 claims abstract description 20
- 239000012279 sodium borohydride Substances 0.000 claims abstract description 20
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 17
- 150000008365 aromatic ketones Chemical class 0.000 claims abstract description 12
- -1 methylols Chemical class 0.000 claims description 191
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims description 43
- 125000004432 carbon atom Chemical group C* 0.000 claims description 42
- 125000000217 alkyl group Chemical group 0.000 claims description 28
- 230000003287 optical effect Effects 0.000 claims description 20
- UOHUDFHWFDUDID-UHFFFAOYSA-N [Cl].C[SiH](C)C Chemical compound [Cl].C[SiH](C)C UOHUDFHWFDUDID-UHFFFAOYSA-N 0.000 claims description 19
- 125000001424 substituent group Chemical group 0.000 claims description 15
- 125000003545 alkoxy group Chemical group 0.000 claims description 9
- 125000004414 alkyl thio group Chemical group 0.000 claims description 9
- 125000005843 halogen group Chemical group 0.000 claims description 9
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 8
- 125000000623 heterocyclic group Chemical group 0.000 claims description 8
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 8
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 8
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 7
- 125000004423 acyloxy group Chemical group 0.000 claims description 6
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 6
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 6
- 230000000707 stereoselective effect Effects 0.000 claims description 3
- IJOOHPMOJXWVHK-UHFFFAOYSA-N chlorotrimethylsilane Chemical compound C[Si](C)(C)Cl IJOOHPMOJXWVHK-UHFFFAOYSA-N 0.000 abstract 2
- DIHSOOPDCJLLHA-UHFFFAOYSA-N bis(4-methoxyphenyl)-pyrrolidin-2-ylmethanol Chemical compound C1=CC(OC)=CC=C1C(O)(C=1C=CC(OC)=CC=1)C1NCCC1 DIHSOOPDCJLLHA-UHFFFAOYSA-N 0.000 abstract 1
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 72
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 36
- 238000006243 chemical reaction Methods 0.000 description 27
- 238000006722 reduction reaction Methods 0.000 description 25
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 24
- 150000001875 compounds Chemical class 0.000 description 20
- 239000000243 solution Substances 0.000 description 17
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N phenylbenzene Natural products C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 15
- 238000003756 stirring Methods 0.000 description 15
- 235000010290 biphenyl Nutrition 0.000 description 14
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 14
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Natural products OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 14
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 12
- CUFNKYGDVFVPHO-UHFFFAOYSA-N azulene Chemical compound C1=CC=CC2=CC=CC2=C1 CUFNKYGDVFVPHO-UHFFFAOYSA-N 0.000 description 11
- UORVGPXVDQYIDP-UHFFFAOYSA-N trihydridoboron Substances B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 10
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 10
- 239000012044 organic layer Substances 0.000 description 10
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 9
- 229910000085 borane Inorganic materials 0.000 description 8
- 229910052740 iodine Inorganic materials 0.000 description 8
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 8
- TVNYNMWSTIOQCP-UHFFFAOYSA-N methyl 5-(4-fluorophenyl)-5-oxopentanoate Chemical class COC(=O)CCCC(=O)C1=CC=C(F)C=C1 TVNYNMWSTIOQCP-UHFFFAOYSA-N 0.000 description 7
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 7
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 6
- OLNTVTPDXPETLC-XPWALMASSA-N ezetimibe Chemical compound N1([C@@H]([C@H](C1=O)CC[C@H](O)C=1C=CC(F)=CC=1)C=1C=CC(O)=CC=1)C1=CC=C(F)C=C1 OLNTVTPDXPETLC-XPWALMASSA-N 0.000 description 6
- 239000011630 iodine Substances 0.000 description 6
- 238000010992 reflux Methods 0.000 description 6
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 229910052801 chlorine Inorganic materials 0.000 description 5
- 238000004821 distillation Methods 0.000 description 5
- 238000001035 drying Methods 0.000 description 5
- 239000000706 filtrate Substances 0.000 description 5
- 238000001914 filtration Methods 0.000 description 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 4
- 229960000815 ezetimibe Drugs 0.000 description 4
- 238000013507 mapping Methods 0.000 description 4
- GRVDJDISBSALJP-UHFFFAOYSA-N methyloxidanyl Chemical group [O]C GRVDJDISBSALJP-UHFFFAOYSA-N 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- 238000010898 silica gel chromatography Methods 0.000 description 4
- 238000005160 1H NMR spectroscopy Methods 0.000 description 3
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 3
- 206010003210 Arteriosclerosis Diseases 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 3
- 125000004799 bromophenyl group Chemical group 0.000 description 3
- 239000000460 chlorine Substances 0.000 description 3
- 239000012230 colorless oil Substances 0.000 description 3
- 125000004802 cyanophenyl group Chemical group 0.000 description 3
- 229910052731 fluorine Inorganic materials 0.000 description 3
- 125000001207 fluorophenyl group Chemical group 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 125000006303 iodophenyl group Chemical group 0.000 description 3
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 3
- 125000001624 naphthyl group Chemical group 0.000 description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- 150000003952 β-lactams Chemical class 0.000 description 3
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical group C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 2
- 125000003006 2-dimethylaminoethyl group Chemical group [H]C([H])([H])N(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 2
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical group C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 2
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 description 2
- 239000003529 anticholesteremic agent Substances 0.000 description 2
- 229940127226 anticholesterol agent Drugs 0.000 description 2
- 208000011775 arteriosclerosis disease Diseases 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 2
- IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical group C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 description 2
- 229910052796 boron Inorganic materials 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- 125000001246 bromo group Chemical group Br* 0.000 description 2
- 125000004106 butoxy group Chemical group [*]OC([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 2
- 125000006630 butoxycarbonylamino group Chemical group 0.000 description 2
- 125000006309 butyl amino group Chemical group 0.000 description 2
- 125000004744 butyloxycarbonyl group Chemical group 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 239000007810 chemical reaction solvent Substances 0.000 description 2
- 125000001309 chloro group Chemical group Cl* 0.000 description 2
- 125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 125000004915 dibutylamino group Chemical group C(CCC)N(CCCC)* 0.000 description 2
- 125000001664 diethylamino group Chemical group [H]C([H])([H])C([H])([H])N(*)C([H])([H])C([H])([H])[H] 0.000 description 2
- 125000006222 dimethylaminomethyl group Chemical group [H]C([H])([H])N(C([H])([H])[H])C([H])([H])* 0.000 description 2
- 125000004914 dipropylamino group Chemical group C(CC)N(CCC)* 0.000 description 2
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 2
- 125000006627 ethoxycarbonylamino group Chemical group 0.000 description 2
- 125000000031 ethylamino group Chemical group [H]C([H])([H])C([H])([H])N([H])[*] 0.000 description 2
- 125000006260 ethylaminocarbonyl group Chemical group [H]N(C(*)=O)C([H])([H])C([H])([H])[H] 0.000 description 2
- 125000006125 ethylsulfonyl group Chemical group 0.000 description 2
- 125000001153 fluoro group Chemical group F* 0.000 description 2
- 150000002240 furans Chemical class 0.000 description 2
- 125000001188 haloalkyl group Chemical group 0.000 description 2
- 125000002883 imidazolyl group Chemical group 0.000 description 2
- 125000006626 methoxycarbonylamino group Chemical group 0.000 description 2
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 2
- 125000004458 methylaminocarbonyl group Chemical group [H]N(C(*)=O)C([H])([H])[H] 0.000 description 2
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 description 2
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 2
- 125000004923 naphthylmethyl group Chemical group C1(=CC=CC2=CC=CC=C12)C* 0.000 description 2
- 125000004115 pentoxy group Chemical group [*]OC([H])([H])C([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 2
- 125000001148 pentyloxycarbonyl group Chemical group 0.000 description 2
- 125000006634 pentyloxycarbonylamino group Chemical group 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 125000006628 propoxycarbonylamino group Chemical group 0.000 description 2
- 125000004742 propyloxycarbonyl group Chemical group 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000035484 reaction time Effects 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 125000004646 sulfenyl group Chemical group S(*)* 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- ILMRJRBKQSSXGY-UHFFFAOYSA-N tert-butyl(dimethyl)silicon Chemical group C[Si](C)C(C)(C)C ILMRJRBKQSSXGY-UHFFFAOYSA-N 0.000 description 2
- 125000001806 thionaphthenyl group Chemical group 0.000 description 2
- WHLUQAYNVOGZST-UHFFFAOYSA-N tifenamil Chemical group C=1C=CC=CC=1C(C(=O)SCCN(CC)CC)C1=CC=CC=C1 WHLUQAYNVOGZST-UHFFFAOYSA-N 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 2
- YKYIFUROKBDHCY-ONEGZZNKSA-N (e)-4-ethoxy-1,1,1-trifluorobut-3-en-2-one Chemical group CCO\C=C\C(=O)C(F)(F)F YKYIFUROKBDHCY-ONEGZZNKSA-N 0.000 description 1
- VDOXIAUNJCHYRC-UHFFFAOYSA-N 1,3-diphenylazetidin-2-one Chemical compound O=C1C(C=2C=CC=CC=2)CN1C1=CC=CC=C1 VDOXIAUNJCHYRC-UHFFFAOYSA-N 0.000 description 1
- 125000001340 2-chloroethyl group Chemical group [H]C([H])(Cl)C([H])([H])* 0.000 description 1
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 1
- ZRNSSRODJSSVEJ-UHFFFAOYSA-N 2-methylpentacosane Chemical compound CCCCCCCCCCCCCCCCCCCCCCCC(C)C ZRNSSRODJSSVEJ-UHFFFAOYSA-N 0.000 description 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- CXDHJGCWMIOAQP-UHFFFAOYSA-N 2-pyridin-3-yl-1,4,5,6-tetrahydropyrimidine;hydrochloride Chemical compound Cl.C1CCNC(C=2C=NC=CC=2)=N1 CXDHJGCWMIOAQP-UHFFFAOYSA-N 0.000 description 1
- 125000006201 3-phenylpropyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- VXIKDBJPBRMXBP-UHFFFAOYSA-N 3H-pyrrole Chemical class C1C=CN=C1 VXIKDBJPBRMXBP-UHFFFAOYSA-N 0.000 description 1
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- 229930182821 L-proline Natural products 0.000 description 1
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- UXMAWJKSGBRJKV-UHFFFAOYSA-N [SiH3][O] Chemical compound [SiH3][O] UXMAWJKSGBRJKV-UHFFFAOYSA-N 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- MNFORVFSTILPAW-UHFFFAOYSA-N azetidin-2-one Chemical class O=C1CCN1 MNFORVFSTILPAW-UHFFFAOYSA-N 0.000 description 1
- KCXMKQUNVWSEMD-UHFFFAOYSA-N benzyl chloride Chemical compound ClCC1=CC=CC=C1 KCXMKQUNVWSEMD-UHFFFAOYSA-N 0.000 description 1
- 229940073608 benzyl chloride Drugs 0.000 description 1
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- BRTALTYTFFNPAC-UHFFFAOYSA-N boroxin Chemical compound B1OBOBO1 BRTALTYTFFNPAC-UHFFFAOYSA-N 0.000 description 1
- 125000006278 bromobenzyl group Chemical group 0.000 description 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- HDFXRQJQZBPDLF-UHFFFAOYSA-L disodium hydrogen carbonate Chemical class [Na+].[Na+].OC([O-])=O.OC([O-])=O HDFXRQJQZBPDLF-UHFFFAOYSA-L 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 1
- YIQOVLOTTPDYRA-UHFFFAOYSA-N methyl 2-(4-fluorophenyl)-5-hydroxypentanoate Chemical class OCCCC(C(=O)OC)C1=CC=C(F)C=C1 YIQOVLOTTPDYRA-UHFFFAOYSA-N 0.000 description 1
- 125000006178 methyl benzyl group Chemical group 0.000 description 1
- 125000004092 methylthiomethyl group Chemical group [H]C([H])([H])SC([H])([H])* 0.000 description 1
- NBVXSUQYWXRMNV-UHFFFAOYSA-N monofluoromethane Natural products FC NBVXSUQYWXRMNV-UHFFFAOYSA-N 0.000 description 1
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 1
- JMJRYTGVHCAYCT-UHFFFAOYSA-N oxan-4-one Chemical compound O=C1CCOCC1 JMJRYTGVHCAYCT-UHFFFAOYSA-N 0.000 description 1
- 229960002429 proline Drugs 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 150000003235 pyrrolidines Chemical class 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 235000015170 shellfish Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 150000003527 tetrahydropyrans Chemical class 0.000 description 1
- 239000004577 thatch Substances 0.000 description 1
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D263/10—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D263/14—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C29/00—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring
- C07C29/132—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring by reduction of an oxygen containing functional group
- C07C29/136—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring by reduction of an oxygen containing functional group of >C=O containing groups, e.g. —COOH
- C07C29/143—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring by reduction of an oxygen containing functional group of >C=O containing groups, e.g. —COOH of ketones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B53/00—Asymmetric syntheses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C29/00—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring
- C07C29/74—Separation; Purification; Use of additives, e.g. for stabilisation
- C07C29/94—Use of additives, e.g. for stabilisation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C33/00—Unsaturated compounds having hydroxy or O-metal groups bound to acyclic carbon atoms
- C07C33/18—Monohydroxylic alcohols containing only six-membered aromatic rings as cyclic part
- C07C33/20—Monohydroxylic alcohols containing only six-membered aromatic rings as cyclic part monocyclic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C67/00—Preparation of carboxylic acid esters
- C07C67/30—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group
- C07C67/31—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group by introduction of functional groups containing oxygen only in singly bound form
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/06—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D205/08—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
A method of stereoselectively producing an optically active alcohol characterized by comprising reducing an aromatic ketone by using an optically active 2-[bis(4-methoxyphenyl)hydroxymethyl]pyrrolidine, sodium borohydride and chlorotrimethylsilane. According to this method, an optically active alcohol showing a high enantioselectivity can be produced even on a large scale.
Description
Technical field
The present invention relates to utilize the chiral reduction reaction to make the method for optical activity alcohol by aromatic ketone.
Background technology
Ezetimibe shown in the following formula: [1-(4-fluorophenyl)-(3R)-[3-(4-fluorophenyl)-(3S)-hydroxypropyl]-(4S)-(4-hydroxyphenyl) azetidine-2-ketone:
Effective as useful serum cholesterol lowering agent in the prevention of atheroma arteriosclerosis and treatment in hydroxyalkyl substituted azetidinone derivative.The manufacture method of relative Diphenylazetidinone derivates also has various report (patent documentation 1-8, non-patent literature 1-2).
These making methods roughly are divided into uses 3-[(5S)-(4-fluorophenyl)-5-hydroxyl pentanoyl]-(4S)-and phenyl-1, the method (method 1) of 3-oxazolidine-2-ketone (VII: numeral is a formula sequence number described later, following identical), structure beta-lactam nucleus; To in (4S)-(4-benzyloxy phenyl)-1-(4-fluorophenyl)-(3R)-[3-(4-fluorophenyl)-3-oxopropyl] azetidine-2-ketone 3 side chains of beta-lactam nucleus such as (X), have the method (method 2) of the derivative chiral reduction of carboxyl.
In the aforesaid method 1; use with due care base (for example trimethyl silyl, t-butyldimethylsilyl etc.) protection 3-[(5S)-(4-fluorophenyl)-5-hydroxyl pentanoyl]-(4S)-and phenyl-1, the synthetic intermediate of the hydroxyl of 3-oxazolidine-2-ketone (VII) (patent documentation 3, patent documentation 6-8).And; 3-[(5S)-(4-fluorophenyl)-5-hydroxyl pentanoyl]-(4S)-phenyl-1; 3-oxazolidine-2-ketone (VII) is by 3-[5-(4-fluorophenyl)-5-oxo pentanoyl]-(4S)-and phenyl-1, the stereo selective microbe reduction reaction synthetic (patent documentation 9) of 3-oxazolidine-2-ketone (VI).
In addition; also report utilizes 3-[5-(4-fluorophenyl)-5-oxo pentanoyl]-(4S)-phenyl-1; the chiral reduction reaction of 3-oxazolidine-2-ketone (VI); synthetic 3-[(5S)-(4-fluorophenyl)-5-hydroxyl pentanoyl]-(4S)-and phenyl-1,3-oxazolidine-2-ketone (VII) (patent documentation 3, patent documentation 10, non-patent literature 8).These methods are for utilizing with (R) shown in the following formula-tetrahydrochysene-1-methyl-3,3-phenylbenzene-1H, 3H-pyrroles (1,2-c) (1,2,3)-oxa-boron pyridine (below be called (R)-MeCBS):
For the borine dimethyl sulphide ether complexes of catalyzer use or the reduction of borine tetrahydrofuran complex, show high enantioselectivity.But, have enantioselectivity and depend on moisture, temperature of reaction in the addition means of borane complex and interpolation speed, the reaction system, produce following formula (XIV):
Shown in the problem (non-patent literature 3) of compound etc.In addition, borine dimethyl sulphide ether complexes or borine tetrahydrofuran complex costliness, toxicity height, borine are gas, therefore handle being not easy.And, though it is above-mentioned (R)-MeCBS is on sale on market, very expensive.Be not as (R)-MeCBS but with (phenylbenzene hydroxymethyl) tetramethyleneimine of (the R)-2-shown in the following formula (XV) when in addition, reaction finishes:
Reclaim, therefore need regenerated operation (operation), must use expensive boron carriers such as trimethylammonium boroxine this moment.
In addition, also reported the chlorine of (-)-B-shown in the use following formula two different loose thatch alkane borines (XVI):
3-[(5S as reductive agent)-(4-fluorophenyl)-5-hydroxyl pentanoyl]-(4S)-phenyl-1, the synthesis method (patent documentation 6) of 3-oxazolidine-2-ketone (VII) and (5S)-(4-fluorophenyl)-5-hydroxypentanoic acid methyl esters (IX).(5S)-(4-fluorophenyl)-5-hydroxypentanoic acid methyl esters (IX) changes 3-[(5S into)-(4-fluorophenyl)-5-hydroxyl pentanoyl]-(4S)-and phenyl-1,3-oxazolidine-2-ketone (VII).Though this reaction also shows highly selective, must the chemical reductive agent of managing metered amount.
In aforesaid method 2, use the chiral reduction reaction of (the R)-MeCBS of (4S)-(4-benzyloxy phenyl)-1-(4-fluorophenyl)-(3R)-[3-(4-fluorophenyl)-3-oxopropyl] azetidine-2-ketone (X) as the borane complex of catalyzer by utilization, with highly-solid selectively manufacturing (4S)-(4-benzyloxy phenyl)-1-(4-fluorophenyl)-(3R)-[(3S)-(4-fluorophenyl)-3-hydroxypropyl] azetidine-2-ketone (XI), this compound is derivatized to ezetimibe (XII) (non-patent literature 1) by removing benzyl.But this technology has the problems referred to above owing to use (R)-MeCBS and borane complex.
In addition, report out the chiral reduction reaction (non-patent literature 4) of the aromatic ketone of the system that utilization contains the optical activity 2-of sodium borohydride, chlorine trimethyl silane and catalytic amount (phenylbenzene methylol) tetramethyleneimine (XV).This reaction is characterised in that, do not need low temperature, use cheapness and the low reagent of toxicity, and then reaction reclaims 2-(phenylbenzene methylol) tetramethyleneimine (XV) with high yield when finishing, and can utilize after the purification process of recrystallization etc. again.By this method; for example at reduction 3-[5-(4-fluorophenyl)-5-oxo pentanoyl]-(4S)-phenyl-1; 3-oxazolidine-2-ketone (VI), manufacturing 3-[(5S)-(4-fluorophenyl)-5-hydroxyl pentanoyl]-(4S)-phenyl-1; during 3-oxazolidine-2-ketone (VIII), can be with high yield, high enantioselectivity manufacturing objective material [1g scale ((R)-2-(phenylbenzene methylol) tetramethyleneimine 10mol%): de87%].But, when enlarging reaction, observe the tendency [10g scale ((R)-2-(phenylbenzene methylol) tetramethyleneimine 10mol%): de74%] that enantioselectivity reduces.Therefore, even if the excellent catalysts that also shows high enantioselectivity down extensive is developed in expectation.
Illustrated that the document of quoting in this specification sheets is as described below.
Patent documentation 1: No. 5631365 specification sheets of United States Patent (USP)
Patent documentation 2: No. 5886171 specification sheets of United States Patent (USP)
Patent documentation 3: No. 6207822 specification sheets of United States Patent (USP)
Patent documentation 4: No. 6133001 specification sheets of United States Patent (USP)
Patent documentation 5: No. 5856473 specification sheets of United States Patent (USP)
Patent documentation 6: the international brochure that discloses No. 2005/066120
Patent documentation 7: Japanese Unexamined Patent Application Publication 2002-531546 communique
Patent documentation 8: TOHKEMY 2005-53931 communique
Patent documentation 9: No. 5618707 specification sheets of United States Patent (USP)
Patent documentation 10: No. 6627757 specification sheets of United States Patent (USP)
Non-patent literature 1:Journal of Organic Chemistry, 1999,
64, 3714
Non-patent literature 2:Journal of Medicinal Chemistry, 1998,
41, 973
Non-patent literature 3:Tetrahedron Letters, 2003,
44, 801
Non-patent literature 4:Tetrahedron Letters, 2001,
41, 10281
Summary of the invention
The object of the present invention is to provide by aromatic ketone and utilize the chiral reduction reaction to make the method for optical activity alcohol, even if this manufacture method also shows high enantioselectivity under extensive.
The inventor furthers investigate for the method that makes the reaction of aromatic ketone chiral reduction make optical activity alcohol, found that by in the chiral reduction reaction of in the past use sodium borohydride, chlorine trimethyl silane and optical activity 2-(phenylbenzene methylol) tetramethyleneimine, using two (4-p-methoxy-phenyl) methylols of optical activity 2-[] tetramethyleneimine (IV) replaces optical activity 2-(phenylbenzene methylol) tetramethyleneimine, even if in extensive, also show high enantioselectivity, and then finish the present invention.
That is, the present invention is a formula V under the Stereoselective manufacturing:
Or
(in the formula, R
1, R
2With following synonym.)
Shown in the method for optical activity alcohol, it is characterized in that, use two (4-p-methoxy-phenyl) methylols of optical activity 2-[shown in sodium borohydride, chlorine trimethyl silane and the following formula (IV)] tetramethyleneimine reduces the aromatic ketone shown in the formula (I).
[in the formula, R
1Be hydrogen atom; halogen atom; low alkyl group (carbonatoms 1-5); low-grade halogenated alkyl (carbonatoms 1-5); elementary alkoxy carbonyl (carbonatoms 1-5); lower alkoxy (carbonatoms 1-5); hydroxyl; nitro; cyano group; low-grade acyloxy (carbonatoms 1-5); lower alkylthio (carbonatoms 1-5); low alkyl group alkylsulfonyl (carbonatoms 1-5); can have substituent amino; can have substituent formamyl; can have substituent aromatic nucleus or heterocycle.
R
2For-(CH
2) n-R
3
[in the formula, n is 1～5 integer.
R
3For hydrogen atom, halogen atom, elementary alkoxy carbonyl (carbonatoms 1-5), lower alkoxy (carbonatoms 1-5), lower alkylthio (carbonatoms 1-5), low alkyl group alkylsulfonyl (carbonatoms 1-5), can have substituent amino, can have substituent formamyl, can have group shown in substituent aromatic nucleus or heterocycle or the following formula (II) or the group shown in the following formula (III).
In the formula, R
4For low alkyl group (carbonatoms 1-5), can have substituent aromatic nucleus, can have substituent benzyl.
R
5And R
6Can be identical or different, be hydrogen atom; halogen atom; low alkyl group (carbonatoms 1-5); low-grade halogenated alkyl (carbonatoms 1-5); elementary alkoxy carbonyl (carbonatoms 1-5); lower alkoxy (carbonatoms 1-5); low-grade acyloxy (carbonatoms 1-5); hydroxyl; nitro; cyano group; can have substituent benzyloxy; replace siloxy-; lower alkylthio (carbonatoms 1-5); low alkyl group alkylsulfonyl (carbonatoms 1-5); can have substituent amino; can have substituent formamyl; can have substituent aromatic nucleus or heterocycle; can have substituent THP trtrahydropyranyl; contain the low alkyl group (carbonatoms 1-5) that can have substituent THP trtrahydropyranyl; the low alkyl group (carbonatoms 1-5) that contains amino that can seasonization.]]
In addition; the present invention is for using two (4-p-methoxy-phenyl) methylols of (R)-2-[shown in sodium borohydride, chlorine trimethyl silane and the following formula (IV)] tetramethyleneimine is 3-[5-(4-the fluorophenyl)-5-oxo pentanoyl shown in the following formula (VI)]-(4S)-phenyl-1; 3-oxazolidine-2-ketone reduction; make the 3-[(5S shown in the following formula (VII))-(4-fluorophenyl)-5-hydroxyl pentanoyl]-(4S)-and phenyl-1, the method for 3-oxazolidine-2-ketone.
In addition, the present invention is for using two (4-p-methoxy-phenyl) methylols of (R)-2-[shown in sodium borohydride, chlorine trimethyl silane and the following formula (IV)] tetramethyleneimine with shown in the following formula (VIII) [5-(4-fluorophenyl)-5-oxopentanoic acid methyl esters reduction makes the method for (5S)-(4-the fluorophenyl)-5-hydroxypentanoic acid methyl esters shown in the following formula (IX).
In addition, the present invention is for using two (4-p-methoxy-phenyl) methylols of (R)-2-[shown in sodium borohydride, chlorine trimethyl silane and the following formula (IV)] tetramethyleneimine is (4S) shown in the following formula (X)-(4-benzyloxy phenyl)-1-(4-fluorophenyl)-(3R)-[3-(4-fluorophenyl)-3-oxopropyl] azetidine-2-ketone reduction, makes the method for (4S)-(4-benzyloxy phenyl)-1-(4-fluorophenyl)-(3R)-[(3S)-(4-fluorophenyl)-3 (the S)-3-hydroxypropyls] azetidine-2-ketone shown in the following formula (XI).
Embodiment
Under regard to the present invention and be elaborated.The R of compound shown in the general formula (I)
1Be in particular hydrogen atom; halogen atom (fluorine atom for example; the chlorine atom; bromine atoms; the iodine atom); alkyl (methyl for example; ethyl; propyl group; butyl; amyl group etc.); haloalkyl (trifluoromethyl for example; 2; 2,2-trifluoroethyl etc.); alkoxy carbonyl (methoxycarbonyl for example; ethoxy carbonyl; propoxycarbonyl; butoxy carbonyl; pentyloxy carbonyl etc.); alkoxyl group (methoxyl group for example; oxyethyl group; propoxy-; butoxy; pentyloxy etc.); hydroxyl; nitro; cyano group; acyloxy (acetoxyl group for example; propionyloxy etc.); alkylthio (methylthio group for example; ethylmercapto group; the rosickyite base; butylthio; penta sulfenyl etc.); alkyl sulphonyl (methylsulfonyl; ethylsulfonyl; third alkylsulfonyl; the fourth alkylsulfonyl; penta alkylsulfonyl etc.); it is (for example amino to have substituent amino; methylamino; ethylamino; propyl group amino; butyl amino; amyl group amino; dimethylamino; diethylamino; dipropyl amino; dibutylamino; diamyl amino; acetylamino; propionyl amino; methoxycarbonyl amino; ethoxy carbonyl amino; propoxycarbonyl amino; butoxy carbonyl amino; pentyloxy carbonyl amino; methylsulfonyl amino; ethylsulfonylamino etc.); can have substituent formamyl (formamyl for example; the methylamino carbonyl; the ethylamino carbonyl; the propyl group aminocarboxyl; the butyl aminocarboxyl; the amyl group aminocarboxyl; dimethylamino; the diethylamino carbonyl; the dipropyl aminocarboxyl; the dibutylamino carbonyl; diamyl aminocarboxyl etc.); can have substituent aromatic nucleus (phenyl for example; fluorophenyl; chloro-phenyl-; bromophenyl; iodophenyl; aminomethyl phenyl; p-methoxy-phenyl; aminophenyl; cyano-phenyl; the methyl thio-phenyl; the methylsulfonyl phenyl; naphthyl; the Azulene base; xenyl; Phenoxyphenyl etc.) or heterocycle (pyridine ring for example; furan nucleus; thiphene ring; imidazole ring; thiazole ring; the cumarone ring; the thionaphthene ring; the benzoglyoxaline ring; benzothiazole ring etc.).
In addition, the R of compound shown in the general formula (I)
2Be in particular alkyl (methyl for example; ethyl; propyl group; butyl; amyl group etc.); alkyl (the chloromethyl for example that contains halogen atom; the 2-chloroethyl; the 3-chloropropyl; the 4-chlorobutyl; 5-chlorine amyl group; brooethyl; the 2-bromotrifluoromethane; the 3-bromopropyl; the 4-brombutyl; 5-bromine amyl group; iodomethyl; 2-iodine ethyl; 3-iodine propyl group; 4-iodine butyl; 5-iodine amyl group etc.); alkyl (the methoxycarbonyl methyl for example that contains methoxycarbonyl; 2-methoxycarbonyl ethyl; 3-methoxycarbonyl propyl group; 4-methoxycarbonyl butyl; 5-methoxycarbonyl amyl group; the 3-ethoxycarbonyl propyl; 3-propoxycarbonyl propyl group; 3-butoxy carbonyl propyl group; 3-pentyloxy carbonyl propyl group); alkyl (the methoxymethyl for example that contains alkoxyl group; the 2-methoxy ethyl; the 3-methoxy-propyl; 4-methoxyl group butyl; 5-methoxyl group amyl group; 4-oxyethyl group butyl; 4-propoxy-butyl; 4-butoxy butyl; 4-pentyloxy butyl etc.); hydroxyl; alkyl (the methylthiomethyl for example that contains alkylthio; 2-methylmercaptoethyl; 3-methylthio group propyl group; 4-methylthio group butyl; 5-methylthio group amyl group; 4-ethylmercapto group butyl; 4-rosickyite Ji Dingji; 4-rosickyite Ji Dingji; 4-penta sulfenyl butyl etc.); alkyl (the methylsulfonyl methyl for example that contains alkyl sulphonyl; 2-methylsulfonyl ethyl; 3-methylsulfonyl propyl group; 4-methylsulfonyl butyl; 5-methylsulfonyl amyl group; 4-ethylsulfonyl butyl; the 4-third alkylsulfonyl butyl; 4-fourth alkylsulfonyl butyl; 4-penta alkylsulfonyl butyl etc.); contain the alkyl that can have substituent amino (dimethylaminomethyl for example; the 2-dimethyl aminoethyl; the 3-dimethylaminopropyl; 4-dimethylamino butyl; 5-dimethylamino amyl group; 4-diethylamino butyl; the amino butyl of 4-dipropyl; the amino butyl of 5-diamyl; the acetylamino methyl; 2-acetylamino ethyl; 3-acetylamino propyl group; 4-acetylamino butyl; 5-acetylamino amyl group; the amino butyl of 4-propionyl; the methoxycarbonyl amino methyl; 2-methoxycarbonyl amino-ethyl; 3-methoxycarbonyl aminopropyl; the amino butyl of 4-methoxycarbonyl; the amino amyl group of 5-methoxycarbonyl; the amino butyl of 4-ethoxy carbonyl; the amino butyl of 4-propoxycarbonyl; the amino butyl of 4-butoxy carbonyl; the amino butyl of 4-pentyloxy carbonyl; the methylsulfonyl amino methyl; 2-methylsulfonyl amino-ethyl; 3-methylsulfonyl aminopropyl; the amino butyl of 4-methylsulfonyl; the amino amyl group of 5-methylsulfonyl; 4-ethylsulfonylamino butyl; the 4-third sulfuryl amino butyl; 4-fourth sulfuryl amino butyl; 4-penta sulfuryl amino butyl etc.); contain the alkyl that can have substituent formamyl (carbamyl ylmethyl for example; 2-formamyl ethyl; 3-formamyl propyl group; 4-formamyl butyl; 5-formamyl amyl group; 3-methylamino carbonyl propyl group; 3-dimethylamino formamyl propyl group; 3-ethylamino carbonyl propyl group; 3-diethylamino carbonyl propyl group; 3-propyl group aminocarboxyl propyl group; 3-dipropyl aminocarboxyl propyl group; 3-butyl aminocarboxyl propyl group; 3-dibutylamino carbonyl propyl group; 3-amyl group aminocarboxyl propyl group; 3-diamyl aminocarboxyl propyl group etc.); contain the alkyl that can have substituent aromatic nucleus [benzyl for example; the 2-phenylethyl; the 3-phenyl propyl; the 4-phenyl butyl; the 5-phenylpentyl; 4-(fluorophenyl) butyl; 4-(chloro-phenyl-) butyl; 4-(bromophenyl) butyl; 4-(iodophenyl) butyl; 4-(aminomethyl phenyl) butyl; 4-(p-methoxy-phenyl) butyl; 4-(aminophenyl) butyl; 4-(cyano-phenyl) butyl; 4-(methyl thio-phenyl) butyl; 4-(methylsulfonyl phenyl) butyl; 4-(naphthyl) butyl; 4-(Azulene base) butyl etc.]; contain (4-(pyridyl) butyl that to have substituent heterocyclic alkyl; 4-(furyl) butyl; 4-(thienyl) butyl; 4-(imidazolyl) butyl; 4-(thiazolyl) butyl; 4-(benzofuryl) butyl; 4-(benzothienyl) butyl; 4-(benzimidazolyl-) butyl; 4-(benzothiazolyl) butyl etc.); or the group shown in the formula (XVII); the perhaps group shown in the formula (XVIII).
R in the general formula (II)
4Be low alkyl group (methyl for example; ethyl; propyl group; sec.-propyl; butyl; isobutyl-; the tertiary butyl; amyl group etc.); can have substituent aromatic nucleus (phenyl for example; fluorophenyl; chloro-phenyl-; bromophenyl; iodophenyl; aminomethyl phenyl; p-methoxy-phenyl; aminophenyl; cyano-phenyl; the methyl thio-phenyl; the methylsulfonyl phenyl; naphthyl; the Azulene base; xenyl; Phenoxyphenyl etc.); can have substituent benzyl (benzyl for example; luorobenzyl; the benzyl chloride base; bromobenzyl; the iodine benzyl; methyl-benzyl; methoxy-benzyl; aminobenzyl; the cyano group benzyl; methyl sulfo-benzyl; the methylsulfonyl benzyl; naphthyl methyl; the Azulene ylmethyl; the xenyl methyl; phenoxy benzyl etc.).
The R of general formula (III)
5And R
6Can be identical or different; be hydrogen atom; halogen atom (fluorine atom for example; the chlorine atom; bromine atoms; the iodine atom); alkyl (methyl for example; ethyl; propyl group; butyl; amyl group etc.); haloalkyl (trifluoromethyl for example; 2; 2,2-trifluoroethyl etc.; chloromethyl; methyl fluoride; iodomethyl; the 2-bromotrifluoromethane; the 3-bromopropyl; the 4-brombutyl; 5-bromine amyl group etc.); elementary alkoxy carbonyl (methoxycarbonyl for example; ethoxy carbonyl; propoxycarbonyl; butoxy carbonyl; pentyloxy carbonyl etc.); lower alkoxy (methoxyl group for example; oxyethyl group; propoxy-; butoxy; pentyloxy etc.); low-grade acyloxy (acetoxyl group for example; propionyloxy etc.); hydroxyl; nitro; cyano group; can have substituent benzyloxy (benzyloxy for example; the fluorine benzyloxy; the chlorine benzyloxy; bromo-benzyloxy-; the iodine benzyloxy; the methyl benzyloxy; methoxyl group benzyloxy base; amino benzyloxy; cyano benzyloxy; methyl sulfo-benzyloxy; the methylsulfonyl benzyloxy; naphthyl methyl oxygen base; Azulene ylmethyl oxygen base; xenyl methyl oxygen base; phenoxy group benzyloxy etc.); replace silyl oxygen base (trimethyl silyl for example; triethylsilyl; the tripropyl silyl; t-butyldimethylsilyl; t-butyldiphenylsilyl etc.); alkylthio (methylthio group for example; ethylmercapto group; the rosickyite base; butylthio; penta sulfenyl etc.); alkyl sulphonyl (methylsulfonyl; ethylsulfonyl; third alkylsulfonyl; the fourth alkylsulfonyl; penta alkylsulfonyl etc.); it is (for example amino to have substituent amino; methylamino; ethylamino; propyl group amino; butyl amino; amyl group amino; dimethylamino; diethylamino; dipropyl amino; dibutylamino; diamyl amino; acetylamino; propionyl amino; methoxycarbonyl amino; ethoxy carbonyl amino; propoxycarbonyl amino; butoxy carbonyl amino; pentyloxy carbonyl amino; methylsulfonyl amino; ethylsulfonylamino etc.); can have substituent formamyl (formamyl for example; the methylamino carbonyl; the ethylamino carbonyl; the propyl group aminocarboxyl; the butyl aminocarboxyl; the amyl group aminocarboxyl; dimethylamino; the diethylamino carbonyl; the dipropyl aminocarboxyl; the dibutylamino carbonyl; diamyl aminocarboxyl etc.); can have substituent aromatic nucleus (phenyl for example; fluorophenyl; chloro-phenyl-; bromophenyl; iodophenyl; aminomethyl phenyl; p-methoxy-phenyl; aminophenyl; cyano-phenyl; the methyl thio-phenyl; the methylsulfonyl phenyl; naphthyl; the Azulene base; xenyl; Phenoxyphenyl etc.) or heterocycle (pyridine ring for example; furan nucleus; thiphene ring; imidazole ring; thiazole ring; the cumarone ring; the thionaphthene ring; the benzoglyoxaline ring; benzothiazole ring etc.); can have substituent THP trtrahydropyranyl (THP trtrahydropyranyl for example; the fluoro THP trtrahydropyranyl; the chloro THP trtrahydropyranyl; the methyl THP trtrahydropyranyl; the methoxyl group THP trtrahydropyranyl; the hydroxy tetrahydro pyranyl; the acetoxyl group THP trtrahydropyranyl; the benzyloxy THP trtrahydropyranyl; trimethyl silyl oxygen base THP trtrahydropyranyl; methoxycarbonyl THP trtrahydropyranyl etc.); contain the alkyl that can have substituent THP trtrahydropyranyl [tetrahydropyrans ylmethyl for example; 2-THP trtrahydropyranyl ethyl; 3-THP trtrahydropyranyl propyl group; 4-THP trtrahydropyranyl butyl; 5-THP trtrahydropyranyl amyl group; 2-(fluoro THP trtrahydropyranyl) ethyl; 2-(chloro THP trtrahydropyranyl) ethyl; 2-(methyl THP trtrahydropyranyl) ethyl; 2-(methoxyl group THP trtrahydropyranyl) ethyl; 2-(hydroxy tetrahydro pyranyl) ethyl; 2-(acetoxyl group THP trtrahydropyranyl) ethyl; 2-(benzyloxy THP trtrahydropyranyl) ethyl; 2-(trimethyl silyl oxygen base THP trtrahydropyranyl) ethyl; 2-(methoxycarbonyl THP trtrahydropyranyl) ethyl etc.]; containing can be by the alkyl of the amino of seasonization (dimethylaminomethyl for example; the 2-dimethyl aminoethyl; the 3-dimethylaminopropyl; 4-dimethylamino butyl; 5-dimethylamino amyl group; 4-diethylamino butyl; the amino butyl of 4-two third classes; the amino butyl of 5-diamyl).
The present invention is for using two (4-p-methoxy-phenyl) methylols of sodium borohydride, chlorine trimethyl silane and optical activity 2-[] tetramethyleneimine (IV) is the reaction of aromatic ketone chiral reduction shown in the above-mentioned general formula (I), makes the method for optical activity alcohol.Two (4-p-methoxy-phenyl) methylols of the optical activity 2-[that uses in the inventive method] tetramethyleneimine (IV) is known substances (for example with reference to No. 5264574 specification sheets of United States Patent (USP)), its manufacture method also can be made (for example with reference to Journal of Chemical Society by D-or L-proline(Pro) according to currently known methods, Perkin Trans 1,1985,2039; Journal of American Society, 1987,109,5551; Tetrahedron, 1993,49,5127; Synthesis, 2004,217).
The method that chiral reduction reaction of the present invention is put down in writing according to above-mentioned non-patent literature 4 is carried out.That is, this method is carried out in a reaction vessel, is made of following 3 stages.
The 1st stage: make the reaction of sodium borohydride and chlorine trimethyl silane.
The 2nd stage: in this reaction solution, add two (4-p-methoxy-phenyl) methylols of optical activity 2-[] tetramethyleneimine, the agent of modulation chiral reduction.
The 3rd stage: in this chiral reduction agent, add aromatic ketone it is reduced, obtain optical activity alcohol.
In above-mentioned the 1st stage, the usage quantity of sodium borohydride and chlorine trimethyl silane is respectively 1 times of mole～1.5 times mole, preferred 1.2 times of mole～1.4 times moles with respect to aromatic ketone.Reaction solvent can use diethyl ether, diisopropyl ether, t-butyl methyl ether, tetrahydrofuran (THF), 1, ether series solvents such as 4-diox, and methylene dichloride, 1, halogen series solvents such as 2-ethylene dichloride, preferred reaction solvent is a tetrahydrofuran (THF).Be reflected under the solvent refluxing temperature and carry out, the reaction times is about 1 hour.
In the 2nd stage, for example by dripping two (4-p-methoxy-phenyl) methylols with optical activity 2-[] tetramethyleneimine is added in the reactant of sodium borohydride and chlorine trimethyl silane, makes its reaction.This is reflected in 0 ℃～40 ℃ the scope and carries out, and preferred temperature of reaction is 15 ℃～30 ℃, and the reaction times is about 30 minutes.Two (4-p-methoxy-phenyl) methylols of optical activity 2-[] usage quantity of tetramethyleneimine is 5 moles of %～20 mole %, is preferably 10 moles of % with respect to aromatic ketone.
In the 3rd stage, for example the aromatic series ketone is added in the chiral reduction agent for preparing in the 1st, 2 stages, carries out reduction reaction by dripping.Reduction reaction is carried out in 0 ℃～40 ℃ scope, and preferable reaction temperature is 15 ℃～30 ℃.
In addition, the 3-[5-of starting raw material of the present invention (4-fluorophenyl)-5-oxo pentanoyl]-(4S)-phenyl-1,3-oxazolidine-2-ketone (VI) and the method manufacturing that 5-(4-fluorophenyl)-5-oxopentanoic acid methyl esters (VIII) can be put down in writing by patent documentation 3 respectively.In addition, (4S)-method manufacturing that (4-benzyloxy phenyl)-1-(4-fluorophenyl)-(3R)-[3-(4-fluorophenyl)-3-oxopropyl] azetidine-2-ketone (X) can be put down in writing by non-patent literature 1 or non-patent literature 2.
And; with 3-[5-(4-fluorophenyl)-5-oxo pentanoyl]-(4S)-phenyl-1; 3-oxazolidine-2-ketone (VI) chiral reduction and the 3-[(5S that obtains)-(4-fluorophenyl)-5-hydroxyl pentanoyl]-(4S)-phenyl-1; 3-oxazolidine-2-ketone (VII) is used for the manufacturing of ezetimibe by the structure of beta-lactam nucleus.In addition; 5-(4-fluorophenyl)-5-oxopentanoic acid methyl esters (VIII) chiral reduction is obtained (5S)-(4-fluorophenyl)-5-hydroxypentanoic acid methyl esters (IX) is used for 3-[(5S)-(4-fluorophenyl)-5-hydroxyl pentanoyl]-(4S)-and phenyl-1, the manufacturing of 3-oxazolidine-2-ketone (VII).And, (4S)-(4-benzyloxy phenyl)-1-(4-fluorophenyl)-(3R)-[3-(4-fluorophenyl)-3-oxopropyl] azetidine-2-ketone (X) chiral reduction is obtained (4S)-(4-benzyloxy phenyl)-1-(4-fluorophenyl)-(3R)-[3 (S)-(4-fluorophenyl)-3-hydroxypropyl] azetidine-2-ketone (XI) be used for the manufacturing of ezetimibe.
Embodiment 1
3-[(5S)-(4-fluorophenyl)-5-hydroxyl pentanoyl]-(4S)-and phenyl-1, the Production Example of 3-oxazolidine-2-ketone
In tetrahydrofuran (THF) (700.0mL) suspension of sodium borohydride (7.45g, 0.197 mole), adding chlorine trimethyl silane (25.0mL, 0.197 mole), reflux 1 hour under 24 ℃.After reaction solution is cooled to 24 ℃, drip two (4-p-methoxy-phenyl) methylols of (R)-2-[] tetrahydrofuran (THF) (280.0mL) solution of tetramethyleneimine (4.41g, 0.014 mole).Stir after 30 minutes, drip 3-[5-(4-fluorophenyl)-5-oxo pentanoyl with times of 1 hour 20 minutes]-(4S)-phenyl-1, tetrahydrofuran (THF) (280.0mL) solution of 3-oxazolidine-2-ketone (compound VI) (50.00g, 0.141 mole).Stir after 10 minutes, be cooled to 4 ℃.After dripping 6 equivalent hydrochloric acid, add entry and toluene.Stir after 30 minutes, with the organic layer separatory.Behind water, saturated sodium bicarbonate sodium water solution, the saturated common salt water washing organic layer, use anhydrous sodium sulfate drying.After the filtration, filtrate is removed in underpressure distillation, obtains 3-[(5S as colorless oil)-(4-fluorophenyl)-5-hydroxyl pentanoyl]-(4S)-and phenyl-1,3-oxazolidine-2-ketone 48.71g.
1H-NMR(CDCl3)δ＝1.56-1.75(m，4H)，1.97(d，J＝3Hz，1H)，2.96-2.99(m，2H)，4.28(dd，J＝3Hz，9Hz，1H)，4.56-4.66(m，1H)，4.68(t，J＝9Hz，1H)，5.40(dd，J＝3Hz，9Hz，1H)，6.98-7.02(m，2H)，7.25-7.37(m，7H).
Measure and (utilize HPLC to measure.Post: CHIRALCELL OD-H (DAICEL), moving phase: ethanol/normal hexane=1/5 (v/v), measure wavelength: 258nm) cis-selectivity of gained target compound (non-mapping excess rate) de (%)=[(S, S) %-(S, R) %] time, be 93%.
Embodiment 2
Two (4-p-methoxy-phenyl) methylols of change as shown in table 1 (R)-2-[] the use mole number (mole %) and 3-[5-(4-the fluorophenyl)-5-oxo pentanoyl of tetramethyleneimine]-(4S)-phenyl-1; the usage quantity (g) of 3-oxazolidine-2-ketone (compound VI); make 3-[(5S similarly to Example 1)-(4-fluorophenyl)-5-hydroxyl pentanoyl]-(4S)-and phenyl-1,3-oxazolidine-2-ketone.Utilize the said determination method to measure the de separately (%) of gained target compound then.It the results are shown in table 1.
In addition; in order to compare; use (R)-2-(phenylbenzene hydroxymethyl) tetramethyleneimine to replace two (4-p-methoxy-phenyl) methylols of (R)-2-[] tetramethyleneimine, make 3-[(5S similarly to Example 1)-(4-fluorophenyl)-5-hydroxyl pentanoyl]-(4S)-and phenyl-1,3-oxazolidine-2-ketone.At this moment, the use mole number of change as shown in table 1 (R)-2-(phenylbenzene methylol) tetramethyleneimine (mole %) and 3-[5-(4-fluorophenyl)-5-oxo pentanoyl]-(4S)-and phenyl-1, the usage quantity (g) of 3-oxazolidine-2-ketone (compound VI).Then, utilize the said determination method to measure the de separately (%) of gained target compound.It the results are shown in table 1.
In addition; in order to compare; use two (4-trifluoromethyl) methylols of (R)-2-[) two (4-p-methoxy-phenyl) methylols of tetramethyleneimine replacement (R)-2-[] tetramethyleneimine; make 3-[(5S similarly to Example 1)-(4-fluorophenyl)-5-hydroxyl pentanoyl]-(4S)-and phenyl-1,3-oxazolidine-2-ketone.At this moment; two (4-trifluoromethyl) hydroxymethyls of change as shown in table 1 (R)-2-[) the use mole number of tetramethyleneimine (mole %) and 3-[5-(4-fluorophenyl)-5-oxo pentanoyl]-(4S)-and phenyl-1, the usage quantity (g) of 3-oxazolidine-2-ketone (compound VI).Then, utilize the said determination method to measure the de separately (%) of gained target compound.It the results are shown in table 1.
Table 1
As shown in Table 1, using two (4-p-methoxy-phenyl) methylols of (R)-2-[of the present invention) tetramethyleneimine is during as catalyzer, even if enlarge reaction scale, also do not see the reduction of de (%), increase on the contrary.On the other hand, when using (R)-2-(phenylbenzene methylol) tetramethyleneimine in the past, when enlarging reaction scale, de (%) reduces.In addition, using two (4-trifluoromethyl) methylols of (R)-2-[) during tetramethyleneimine, even if reaction scale is little, de (%) also can reduce significantly.
Embodiment 3
(5S)-Production Example of (4-fluorophenyl)-5-hydroxypentanoic acid methyl esters
In tetrahydrofuran (THF) (63.0mL) suspension of sodium borohydride (0.61g, 0.01606 mole), adding chlorine trimethyl silane (2.0mL, 0.01606 mole), reflux 1 hour under 20 ℃.After reaction solution is cooled to 24 ℃, drip two (4-p-methoxy-phenyl) methylols of (R)-2-[] tetrahydrofuran (THF) (10.0mL) solution of tetramethyleneimine (0.42g, 0.00134 mole).Stir after 30 minutes, with tetrahydrofuran (THF) (10.0mL) solution of 45 minutes time Dropwise 5s-(4-fluorophenyl)-5-oxopentanoic acid methyl esters (compound VIII) (3.00g, 0.01338 mole).Stir after 1 hour 30 minutes, be cooled to 2 ℃.After dripping 6 equivalent hydrochloric acid, add entry and ethyl acetate.Stir after 30 minutes, with the organic layer separatory.Behind water, saturated sodium bicarbonate aqueous solution, the saturated common salt water washing organic layer, use anhydrous sodium sulfate drying.After the filtration, filtrate is removed in underpressure distillation, uses silica gel column chromatography (ethyl acetate/normal hexane) purifying gained residue, obtains (5S)-(4-fluorophenyl)-5-hydroxypentanoic acid methyl esters 2.79g as colorless oil.
1H-NMR(CDCl3)δ＝1.59-1.80(m，4H)，2.21(s，1H)，2.32-2.36(m，2H)，3.65(s，3H)，4.63-4.68(m，1H)，7.00-7.04(m，2H)，7.26-7.32(m，2H).
Measure and (utilize HPLC to measure.Post: CHIRALPAK AD (DAICEL), moving phase: ethanol/normal hexane=1/20 (v/v), mensuration wavelength: the 258nm) enantioselectivity of gained target compound (mapping excess rate) ee (%)=[(S) %-(S) %].The results are shown in table 2.
Comparative example 1
In tetrahydrofuran (THF) (21.0mL) suspension of sodium borohydride (0.202g, 0.005352 mole), adding chlorine trimethyl silane (0.68mL, 0.005352 mole), reflux 1 hour under 21 ℃.After reaction solution is cooled to 24 ℃, drip (R)-2-(the phenylbenzene methylol] tetrahydrofuran (THF) (5.0mL) solution of tetramethyleneimine (0.114g, 0.0004466 mole).Stir after 30 minutes, with tetrahydrofuran (THF) (5.0mL) solution of 48 minutes time Dropwise 5s-(4-fluorophenyl)-5-oxopentanoic acid methyl esters (compound VIII) (1.00g, 0.00446 mole).Stir after 30 minutes, be cooled to 2 ℃.After dripping 6 equivalent hydrochloric acid, add entry and ethyl acetate.Stir after 30 minutes, with the organic layer separatory.Behind water, saturated sodium bicarbonate aqueous solution, the saturated common salt water washing organic layer, use anhydrous sodium sulfate drying.After the filtration, filtrate is removed in underpressure distillation, uses silica gel column chromatography (ethyl acetate/normal hexane) purifying gained residue, obtains (5S)-(4-fluorophenyl)-5-hydroxypentanoic acid methyl esters 0.90g as colorless oil.Utilize the ee% of the assay method mensuration gained target compound of embodiment 3 records.The results are shown in table 2.
Table 2
As shown in Table 2, using two (4-p-methoxy-phenyl) methylols of (R)-2-[of the present invention) tetramethyleneimine is during as catalyzer, compares during with (R)-2-(phenylbenzene methylol) tetramethyleneimine of using in the past, even if enlarge reaction scale, ee (%) is also big.
Embodiment 4
(4S)-Production Example of (4-benzyloxy phenyl)-1-(4-fluorophenyl)-(3R)-[(3S)-(4-fluorophenyl)-3-hydroxypropyl] azetidine-2-ketone
In tetrahydrofuran (THF) (15.1mL) suspension of sodium borohydride (0.099g, 0.002613 mole), adding chlorine trimethyl silane (0.33mL, 0.002613 mole), reflux 1 hour under 19 ℃.After reaction solution is cooled to 22 ℃, drip two (4-p-methoxy-phenyl) methylols of (R)-2-[] tetrahydrofuran (THF) (5.2mL) solution of tetramethyleneimine (0.063g, 0.000201 mole).Stir after 30 minutes, drip tetrahydrofuran (THF) (5.2mL) solution of (4S)-(4-benzyloxy phenyl)-1-(4-fluorophenyl)-(3R)-[3-(4-fluorophenyl)-3-hydroxypropyl] azetidines-2-ketone (compounds X) (1.00g, 0.00201 mole) with times of 8 minutes.Stir after 1 hour, be cooled to 2 ℃.After dripping 6 equivalent hydrochloric acid, add entry and ethyl acetate.Stir after 30 minutes, with the organic layer separatory.Behind water, saturated sodium bicarbonate aqueous solution, the saturated common salt water washing organic layer, use anhydrous sodium sulfate drying.After the filtration, filtrate is removed in underpressure distillation, use silica gel column chromatography (ethyl acetate/normal hexane) purifying gained residue, obtain (4S)-(4-benzyloxy phenyl)-1-(4-fluorophenyl)-(3R)-[(3S)-(4-fluorophenyl)-3-hydroxypropyl] azetidine-2-ketone 0.89g as white crystals.
1H-NMR(CDCl3)δ＝1.88-2.01(m，4H)，2.19(d，J＝4Hz，1H)，3.07(dt，J＝2Hz，8Hz，1H)，4.57(d，J＝2Hz，1H)，4.71-4.73(m，1H)，5.29(s，2H)，6.90-7.03(m，6H)，7.21-7.43(m，11H).
Measure and (utilize HPLC to measure.Post: CHIRALPAK AD (DAICEL), moving phase: ethanol/normal hexane=1/9 (v/v), mensuration wavelength: the 258nm) enantioselectivity of gained target compound (mapping excess rate) ee (%)=[(S) %-(R) %].The results are shown in table 3.
Comparative example 2
In tetrahydrofuran (THF) (15.1mL) suspension of sodium borohydride (0.099g, 0.002613 mole), adding chlorine trimethyl silane (0.33mL, 0.002613 mole), reflux 1 hour under 19 ℃.After reaction solution is cooled to 22 ℃, drip tetrahydrofuran (THF) (5.2mL) solution of (R)-2-(phenylbenzene hydroxymethyl) tetramethyleneimine (0.051g, 0.000201 mole).Stir after 30 minutes, drip tetrahydrofuran (THF) (5.2mL) solution of (4S)-(4-benzyloxy phenyl)-1-(4-fluorophenyl)-(3R)-[3-(4-fluorophenyl)-3-oxopropyl] azetidines-2-ketone (compounds X) (1.00g, 0.00201 mole) with times of 7 minutes.Stir after 1 hour 10 minutes, be cooled to 2 ℃.After dripping 6 equivalent hydrochloric acid, add entry and ethyl acetate.Stir after 30 minutes, with the organic layer separatory.Behind water, saturated sodium bicarbonate aqueous solution, the saturated common salt water washing organic layer, use anhydrous sodium sulfate drying.After the filtration, filtrate is removed in underpressure distillation, use silica gel column chromatography (ethyl acetate/normal hexane) purifying gained residue, obtain (4S)-(4-benzyloxy phenyl)-1-(4-fluorophenyl)-(3R)-[(3S)-(4-fluorophenyl)-3-hydroxypropyl] azetidine-2-ketone 0.92g as white crystals.
Utilize the ee% of the assay method mensuration gained target compound of embodiment 4 records.The results are shown in table 3.
Table 3
As shown in Table 3, using two (4-p-methoxy-phenyl) methylols of (R)-2-[of the present invention) tetramethyleneimine is during as catalyzer, compares during with (R)-2-(phenylbenzene methylol) tetramethyleneimine of using in the past, and when reaction scale was identical, ee (%) was big about 2 times.
Industrial applicability
The method of reducing of the application of the invention, even if extensive lower, also can be with high mapping choosing Selecting property is made optical activity alcohol from aromatic ketone. Therefore, the present invention for Production Example as at artery congee Useful serum cholesterol lowering agent replaces according to the pool in the prevention of sample arteriosclerosis and the treatment Rice shellfish: [1-(4-fluorophenyl)-(3R)-[3-(4-fluorophenyl)-(3S)-hydroxypropyl]-(4S)-(4-hydroxyphenyl) azetidine-optical activity alcohols such as 2-ketone (XII) are useful. In addition, this It is bright because two (the 4-of 2-[of catalyst are reclaimed in the operations such as extraction when finishing by reaction with high yield Methoxyphenyl) methylol) pyrrolidines (IV) therefore has after the purification procedures such as recrystallization The advantage that can recycle. In addition, because reaction is carried out near room temperature, therefore having does not need The advantage of low temperature.
Claims (4)
1. the method for optical activity alcohol shown in the formula V under the Stereoselective manufacturing,
Or
(in the formula, R
1, R
2With following synonym.)
It is characterized in that, use two (4-p-methoxy-phenyl) methylols of optical activity 2-[shown in sodium borohydride, chlorine trimethyl silane and the following formula (IV)] tetramethyleneimine is the reduction of the aromatic ketone shown in the formula (I),
[in the formula, R
1Be hydrogen atom; halogen atom; low alkyl group (carbonatoms 1-5); low-grade halogenated alkyl (carbonatoms 1-5); elementary alkoxy carbonyl (carbonatoms 1-5); lower alkoxy (carbonatoms 1-5); hydroxyl; nitro; cyano group; low-grade acyloxy (carbonatoms 1-5); lower alkylthio (carbonatoms 1-5); low alkyl group alkylsulfonyl (carbonatoms 1-5); can have substituent amino; can have substituent formamyl; can have substituent aromatic nucleus or heterocycle
R
2For-(CH
2) n-R
3,
[in the formula, n is 1～5 integer.R
3For hydrogen atom, halogen atom, elementary alkoxy carbonyl (carbonatoms 1-5), lower alkoxy (carbonatoms 1-5), lower alkylthio (carbonatoms 1-5), low alkyl group alkylsulfonyl (carbonatoms 1-5), can have substituent amino, can have substituent formamyl, can have group shown in substituent aromatic nucleus or heterocycle or the following formula (II) or the group shown in the following formula (III)
In the formula, R
4For low alkyl group (carbonatoms 1-5), can have substituent aromatic nucleus, can have substituent benzyl,
R
5And R
6Can be identical or different; be hydrogen atom; halogen atom; low alkyl group (carbonatoms 1-5); low-grade halogenated alkyl (carbonatoms 1-5); elementary alkoxy carbonyl (carbonatoms 1-5); lower alkoxy (carbonatoms 1-5); low-grade acyloxy (carbonatoms 1-5); hydroxyl; nitro; cyano group; can have substituent benzyloxy; replace siloxy-; lower alkylthio (carbonatoms 1-5); low alkyl group alkylsulfonyl (carbonatoms 1-5); can have substituent amino; can have substituent formamyl; can have substituent aromatic nucleus or heterocycle; can have substituent THP trtrahydropyranyl; contain the low alkyl group (carbonatoms 1-5) that can have substituent THP trtrahydropyranyl; the low alkyl group (carbonatoms 1-5) that contains amino that can seasonization ,]].
2. use two (4-p-methoxy-phenyl) methylols of (R)-2-[shown in sodium borohydride, chlorine trimethyl silane and the following formula (IV)] tetramethyleneimine is 3-[5-(4-the fluorophenyl)-5-oxo pentanoyl shown in the following formula (VI)]-(4S)-phenyl-1; 3-oxazolidine-2-ketone reduction; make the 3-[(5S shown in the following formula (VII))-(4-fluorophenyl)-5-hydroxyl pentanoyl]-(4S)-and phenyl-1, the method for 3-oxazolidine-2-ketone.
3. use two (4-p-methoxy-phenyl) methylols of (R)-2-[shown in sodium borohydride, chlorine trimethyl silane and the following formula (IV)] tetramethyleneimine with shown in the following formula (VIII) [5-(4-fluorophenyl)-5-oxopentanoic acid methyl esters reduction makes the method for (5S)-(4-the fluorophenyl)-5-hydroxypentanoic acid methyl esters shown in the following formula (IX).
4. using two (4-p-methoxy-phenyl) methylols of (R)-2-[shown in sodium borohydride, chlorine trimethyl silane and the following formula (IV)] tetramethyleneimine is (4S) shown in the following formula (X)-(4-benzyloxy phenyl)-1-(4-fluorophenyl)-(3R)-[3-(4-fluoropropyl)-3-oxopropyl] azetidine-2-ketone reduction, makes the method for (4S)-(4-benzyloxy phenyl)-1-(4-fluorophenyl)-(3R)-[(3S)-(4-fluorophenyl)-3 (the S)-3-hydroxypropyls] azetidine-2-ketone shown in the following formula (XI).
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2006038964 | 2006-02-16 | ||
| JP038964/2006 | 2006-02-16 | ||
| PCT/JP2007/052900 WO2007094480A1 (en) | 2006-02-16 | 2007-02-13 | Method of producing optically active alcohol |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101384532A true CN101384532A (en) | 2009-03-11 |
| CN101384532B CN101384532B (en) | 2013-01-02 |
Family
ID=38371655
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2007800054584A Expired - Fee Related CN101384532B (en) | 2006-02-16 | 2007-02-13 | Process for preparing optically active alcohols |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US7956182B2 (en) |
| EP (1) | EP1988071A4 (en) |
| JP (1) | JP5001252B2 (en) |
| KR (1) | KR101074968B1 (en) |
| CN (1) | CN101384532B (en) |
| CA (1) | CA2642388C (en) |
| IL (1) | IL193154A (en) |
| MX (1) | MX2008010235A (en) |
| WO (1) | WO2007094480A1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102532097A (en) * | 2011-10-19 | 2012-07-04 | 华东理工大学 | Asymmetric synthesis method of duloxetine intermediate-(S)-N, N-dimethyl-3-hydroxy-3-(2-thienyl)-1-propylamine |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1922304A2 (en) * | 2005-09-08 | 2008-05-21 | Teva Pharmaceutical Industries Ltd | Processes for the preparation of (3r,4s)-4-((4-benzyloxy)phenyl)-1-(4-fluorophenyl)-3-((s)-3-(4-fluorophenyl)-3-hydroxypropyl)-2-azetidinone, an intermediate for the synthesis of ezetimibe |
| US20090047716A1 (en) * | 2007-06-07 | 2009-02-19 | Nurit Perlman | Reduction processes for the preparation of ezetimibe |
| CA2757722C (en) | 2009-04-01 | 2018-05-22 | Matrix Laboratories Ltd. | Enzymatic process for the preparation of (s)-5-(4-fluoro-phenyl)-5-hydroxy- 1morpholin-4-yl-pentan-1-one, an intermediate of ezetimibe and further conversion to ezetimibe |
| WO2015039675A1 (en) | 2013-09-23 | 2015-03-26 | Pharmathen S.A. | Novel process for the preparation of ezetimibe intermediates |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US613301A (en) * | 1898-11-01 | Yoke for railway-conduits | ||
| US5039802A (en) * | 1990-04-18 | 1991-08-13 | Merck & Co., Inc. | Arylation process for preparation of chiral catalysts for ketone reduction |
| US5189177A (en) * | 1990-04-18 | 1993-02-23 | Merck & Co., Inc. | Chiral boron catalysts for reduction of ketones and process for their preparation |
| US5631365A (en) * | 1993-09-21 | 1997-05-20 | Schering Corporation | Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents |
| US5618707A (en) * | 1996-01-04 | 1997-04-08 | Schering Corporation | Stereoselective microbial reduction of 5-fluorophenyl-5-oxo-pentanoic acid and a phenyloxazolidinone condensation product thereof |
| WO1997016424A1 (en) * | 1995-11-02 | 1997-05-09 | Schering Corporation | Process for preparing 1-(4-fluorophenyl)-3(r)-(3(s)-hydroxy-3-([phenyl or 4-fluorophenyl])-propyl)-4(s)-(4-hydroxyphenyl)-2-azetidinone |
| US5886171A (en) * | 1996-05-31 | 1999-03-23 | Schering Corporation | 3-hydroxy gamma-lactone based enantioselective synthesis of azetidinones |
| US6090950A (en) * | 1996-08-23 | 2000-07-18 | Zeeland Chemicals, Inc. | Chiral hydride complexes |
| US6133001A (en) | 1998-02-23 | 2000-10-17 | Schering Corporation | Stereoselective microbial reduction for the preparation of 1-(4-fluorophenyl)-3(R)-[3(S)-Hydroxy-3-(4-fluorophenyl)propyl)]-4(S)-(4 -hydroxyphenyl)-2-azetidinone |
| US6207822B1 (en) * | 1998-12-07 | 2001-03-27 | Schering Corporation | Process for the synthesis of azetidinones |
| ATE297892T1 (en) | 1998-12-07 | 2005-07-15 | Schering Corp | METHOD FOR PRODUCING AZETIDINONES |
| US6218585B1 (en) * | 2000-04-20 | 2001-04-17 | Mine Safety Appliances Company | Increasing enatioselectivity in reductions with borane reagents |
| SK287408B6 (en) * | 2001-03-28 | 2010-09-07 | Schering Corporation | A process for preparing intermediate compounds to the synthesis of azetidinone |
| WO2005066120A2 (en) | 2003-12-30 | 2005-07-21 | Ranbaxy Laboratories Limited | Process for asymmetric synthesis of hydroxy-alkyl substituted azetidinone derivatives |
| EP1922304A2 (en) * | 2005-09-08 | 2008-05-21 | Teva Pharmaceutical Industries Ltd | Processes for the preparation of (3r,4s)-4-((4-benzyloxy)phenyl)-1-(4-fluorophenyl)-3-((s)-3-(4-fluorophenyl)-3-hydroxypropyl)-2-azetidinone, an intermediate for the synthesis of ezetimibe |
-
2007
- 2007-02-13 KR KR1020087019164A patent/KR101074968B1/en not_active IP Right Cessation
- 2007-02-13 WO PCT/JP2007/052900 patent/WO2007094480A1/en active Application Filing
- 2007-02-13 MX MX2008010235A patent/MX2008010235A/en active IP Right Grant
- 2007-02-13 EP EP07714428A patent/EP1988071A4/en not_active Withdrawn
- 2007-02-13 CN CN2007800054584A patent/CN101384532B/en not_active Expired - Fee Related
- 2007-02-13 JP JP2008500579A patent/JP5001252B2/en not_active Expired - Fee Related
- 2007-02-13 US US12/224,098 patent/US7956182B2/en not_active Expired - Fee Related
- 2007-02-13 CA CA2642388A patent/CA2642388C/en not_active Expired - Fee Related
-
2008
- 2008-07-31 IL IL193154A patent/IL193154A/en not_active IP Right Cessation
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102532097A (en) * | 2011-10-19 | 2012-07-04 | 华东理工大学 | Asymmetric synthesis method of duloxetine intermediate-(S)-N, N-dimethyl-3-hydroxy-3-(2-thienyl)-1-propylamine |
Also Published As
| Publication number | Publication date |
|---|---|
| IL193154A0 (en) | 2009-02-11 |
| CA2642388A1 (en) | 2007-08-23 |
| EP1988071A1 (en) | 2008-11-05 |
| MX2008010235A (en) | 2008-10-23 |
| JP5001252B2 (en) | 2012-08-15 |
| KR20080093433A (en) | 2008-10-21 |
| IL193154A (en) | 2011-10-31 |
| US20090062527A1 (en) | 2009-03-05 |
| US7956182B2 (en) | 2011-06-07 |
| WO2007094480A1 (en) | 2007-08-23 |
| CN101384532B (en) | 2013-01-02 |
| JPWO2007094480A1 (en) | 2009-07-09 |
| EP1988071A4 (en) | 2011-10-12 |
| CA2642388C (en) | 2013-11-05 |
| KR101074968B1 (en) | 2011-10-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8178665B2 (en) | Process for the production of ezetimibe and intermediates used in this process | |
| Arai et al. | Phase-transfer-catalyzed asymmetric Darzens reaction | |
| CN101384532B (en) | Process for preparing optically active alcohols | |
| Bhuniya et al. | Design, synthesis, and application of chiral nonracemic lithium amide bases in enantioselective deprotonation of epoxides | |
| JP2007538041A (en) | Method for producing diphenylazetidinone derivative | |
| Margalef et al. | Phosphite‐thioether/selenoether Ligands from Carbohydrates: An Easily Accessible Ligand Library for the Asymmetric Hydrogenation of Functionalized and Unfunctionalized Olefins | |
| Palomo et al. | A Study on the Asymmetric Synthesis of β-Lactams through Double Stereodifferentiating Cycloaddition Reactions | |
| CN101935309A (en) | Method for preparing ezetimibe and intermediate thereof | |
| JP2002088054A (en) | Optical active intermediate and method for producing the same | |
| JP2581740B2 (en) | Optically active α-aminoaldehyde | |
| CN102516152B (en) | Alpha-difluoro carbonyl substituted chiral tert-alcohol compound, its synthetic method and application thereof | |
| JP6392749B2 (en) | Compounds and methods | |
| AU2006205663A1 (en) | Process for the manufacture of substituted propionic acids | |
| JP7109056B2 (en) | Method for producing S-ICA ribosylhomocysteine | |
| Ohkura et al. | Diastereoselective Synthesis of S-tert-Butyl-β-(trifluoromethyl) isocysteine | |
| JP5030270B2 (en) | Process for producing β-hydroxycarbonyl compound | |
| CA2554297A1 (en) | Catalytic asymmetric synthesis of optically active .alpha.-halo-carbonyl compounds | |
| IL170728A (en) | Optically active copper catalyst composition | |
| CN101835745B (en) | Process for production of disulfonic acid compound, asymmetric mannich catalyst, process for production of beta-aminocarbonyl derivative, and novel disulfonate salt | |
| KR20170093017A (en) | METHOD FOR SYNTHESIZING β-AMINO-DITHIOESTER COMPOUND AND β-AMINO-DITHIOESTER COMPOUND SYNTHESIZED BY THE METHOD | |
| US6965038B2 (en) | Acylated aminothiol compound | |
| US20220235082A1 (en) | Catalysts | |
| JPH03115260A (en) | Improved method for synthesis of beta-lactam using metal compound | |
| Jayasuriya | Asymmetric alkenyl zirconocene/zinc additions to aldehydes and synthetic efforts toward pseudotrienic acid A | |
| US20040236151A1 (en) | Process to produce enantiomerically enriched 1-aryl-and 1-heteroaryl-2-aminoethanols |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20130102 Termination date: 20180213 |